[HTML][HTML] Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group - The Lancet Respiratory Medicine, 2021 - Elsevier
Background Colchicine has been proposed as a treatment for COVID-19 based on its anti-
inflammatory actions. We aimed to evaluate the efficacy and safety of colchicine in patients …

Colchicine in recently hospitalized patients with COVID-19: a randomized controlled trial (COL-COVID)

DA Pascual-Figal, AE Roura-Piloto… - … Journal of General …, 2021 - Taylor & Francis
Background Colchicine has been proposed as a potential therapy in coronavirus disease
2019 (COVID-19) due to their anti-inflammatory actions. Methods The COL-COVID study …

A case control study to evaluate the impact of colchicine on patients admitted to the hospital with moderate to severe COVID‐19 infection

T Sandhu, A Tieng, S Chilimuri… - Canadian Journal of …, 2020 - Wiley Online Library
Background. Colchicine has been used in conditions such as periodic febrile illness, acute
pericarditis, and gouty arthritis, all having a common hyperinflammatory response as seen in …

Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial

MI Lopes, LP Bonjorno, MC Giannini, NB Amaral… - RMD open, 2021 - rmdopen.bmj.com
Objective To evaluate whether the addition of colchicine to standard treatment for COVID-19
results in better outcomes. Design We present the results of a randomised, double-blinded …

[HTML][HTML] Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre …

JC Tardif, N Bouabdallaoui, PL L'allier… - The Lancet …, 2021 - thelancet.com
Background Evidence suggests a role for excessive inflammation in COVID-19
complications. Colchicine is an oral anti-inflammatory medication beneficial in gout …

[HTML][HTML] Colchicine use in patients with COVID-19: A systematic review and meta-analysis

L Chiu, CH Lo, M Shen, N Chiu, R Aggarwal, J Lee… - PLoS …, 2021 - journals.plos.org
Introduction Colchicine may inhibit inflammasome signaling and reduce proinflammatory
cytokines, a purported mechanism of COVID-19 pneumonia. The aim of this systematic …

Efficacy of colchicine in non-hospitalized patients with COVID-19

JC Tardif, N Bouabdallaoui, PL L'Allier, D Gaudet… - Medrxiv, 2021 - medrxiv.org
Background Evidence suggests the role of an inflammatory storm in COVID-19
complications. Colchicine is an orally administered, anti-inflammatory medication beneficial …

[HTML][HTML] Colchicine to weather the cytokine storm in hospitalized patients with COVID-19

L Brunetti, O Diawara, A Tsai, BL Firestein… - Journal of clinical …, 2020 - mdpi.com
The repurposing of colchicine for the treatment of COVID-19 was suggested based in its
immunomodulatory, anti-inflammatory, and anti-viral properties. We performed a single …

Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial

J Dorward, LM Yu, G Hayward, BR Saville… - British Journal of …, 2022 - bjgp.org
Background Colchicine has been proposed as a COVID-19 treatment. Aim To determine
whether colchicine reduces time to recovery and COVID-19-related admissions to hospital …

Effect of colchicine vs usual care alone on intubation and 28-day mortality in patients hospitalized with COVID-19: a randomized clinical trial

R Diaz, A Orlandini, N Castellana, A Caccavo… - JAMA Network …, 2021 - jamanetwork.com
Importance Hospitalized patients with COVID-19 pneumonia have high rates of morbidity
and mortality. Objective To assess the efficacy of colchicine in hospitalized patients with …